discontinued

BM1087 Epstein Barr Virus / EBV Capsid Antigen (VCA gp160) antibody

See related secondary antibodies

Search for all "Epstein Barr Virus / EBV"

0.2 mg / €370.00

Quick Overview

Mouse anti Epstein Barr Virus / EBV 2E3

BM1087

Product Description for Epstein Barr Virus / EBV

Mouse anti Epstein Barr Virus / EBV 2E3.
Properties: Capsid Antigen (VCA gp160)
Presentation: Purified
Product is tested for Frozen Sections, Enzyme Immunoassay, Immunocytochemistry/Immunofluorescence, Western blot / Immunoblot.

Properties for Epstein Barr Virus / EBV

Product Category Primary Antibodies
Quantity 0.2 mg
Synonyms HHV-4, HHV4
Presentation Purified
Applications C, E, ICC/IF, WB
Clonality Monoclonal
Clone 2E3
Host Mouse
Isotype IgG2a
Molecular weight 110 kDa (VCA glycoprotein), 150 kDa (non-glycosylated VCA major capsid antigen)
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer Acris Antibodies GmbH
Material safety datasheet MSDS for Monoclonal Antibodies (de)

Datasheet Extract

Immunogen
Immunogen:
EBV wild type
Property Capsid Antigen, VCA gp160
Isotype control AM03096PU-N
Application ELISA. 
Western Blot (1/100-1/1000).
Immunofluorescence: (1/50-1/500).
Background Epstein-Barr virus (EBV), also designated human herpesvirus 4 (HHV-4), is a member of the herpesvirus family and is one of the most common human viruses, infecting about 90% of the population. EBV infects only B lymphocytes and, though often asymptomatic, it can cause infectious mononucleosis, a disease characterized by fatigue, fever, sore throat and muscle soreness. The linear genome of EBV circularizes once it enters the cell and exists there as an episome. EBV may play a role in the development of both Burkitt lymphoma, a disease in which a tumor can form on the mandible or maxilla, and nasopharyngeal carcinoma, a tumor found in the upper respiratory tract, most commonly in the nasopharynx. The viral capsid antigen (VCA) of EBV is used as a marker for screening for viral infection as well as nasopharyngeal carcinoma, and many antigens from the viral capsid are used in diagnostic tests.
Concentration 1.0 mg/ml
Product Citations
Originator or purchased from resellers:
  1. Feng X, Zhang J, Chen WN, Ching CB. Proteome profiling of Epstein-Barr virus infected nasopharyngeal carcinoma cell line: identification of potential biomarkers by comparative iTRAQ-coupled 2D LC/MS-MS analysis. J Proteomics. 2011 Apr 1;74(4):567-76. doi: 10.1016/j.jprot.2011.01.017. Epub 2011 Feb 4. PubMed PMID: 21296196.
General Readings
  1. Luka J, Miller G, Jörnvall H, Pearson GR. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. J Virol. 1986 Jun;58(3):748-56. PubMed PMID: 2422401. (Free PMC Article available)
  2. Goldschmidts WL, Ginsburg M, Pearson GR. Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide. Virology. 1989 May;170(1):330-3. PubMed PMID: 2541553.
  3. Fan, J.A. 1990. Expression of the Epstein-Barr virus p150 viral capsid antigen in Escherichia coli for the use as antigen in diagnostic tests. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 11: 381-387.
  4. Gorgievski-Hrisoho M, Hinderer W, Nebel-Schickel H, Horn J, Vornhagen R, Sonneborn HH, et al. Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology. J Clin Microbiol. 1990 Oct;28(10):2305-11. PubMed PMID: 2172287. (Free PMC Article available)
  5. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, et al. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol. 1999 Mar;19(3):1651-60. PubMed PMID: 10022853. (Free PMC Article available, 10 images available)
  6. Tranchand-Bunel, D., et al. 1999. Detection of human antibodies using “convergent” combinatorial peptide libraries or “mixotopes” designed from a nonvariable antigen: application to the EBV viral capsid antigen p18. J. Pept. Res. 52: 495-508.
  7. Gan, Y.Y., et al. 2001. Epstein-Barr viral antigens used in the diagnosis of nasopharyngeal carcinoma. J. Biomed. Sci. 3: 159-169.
  8. Kantakamalakul, W., et al. 2001. Specific IgA antibody to Epstein-Barr viral capsid antigen: a better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction. Asian Pac. J. Allergy Immunol. 18: 221-226.
  9. Spender LC, Lucchesi W, Bodelon G, Bilancio A, Karstegl CE, Asano T, et al. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol. 2006 Oct;87(Pt 10):2859-67. PubMed PMID: 16963743.
Storage Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
Avoid repeated freezing and thawing.
Shelf life: one year from despatch.
Format
Purification:
Affinity Chromatography on Protein A
Buffer System:
PBS
Preservatives:
0.09% Sodium Azide
State:
Liquid purified IgG fraction
Purified
Specificity
Specificity:
This antibody recognises a 160 kDa VCA antigen in immunoblotting.
Does not react with CMV, ADV, VSZ, HSV or other EBV antigens.

Accessory Products

  • LinkedIn